Quinoxaline Moiety: A Potential Scaffold against Mycobacterium tuberculosis
Background. The past decades have seen numerous efforts to develop new antitubercular agents. Currently, the available regimens are lengthy, only partially effective, and associated with high rates of adverse events. The challenge is therefore to develop new agents with faster and more efficient action. The versatile quinoxaline ring possesses a broad spectrum of pharmacological activities, ensuring considerable attention to it in the field of medicinal chemistry. Objectives. In continuation of our program on the pharmacological activity of quinoxaline derivatives, this review focuses on potential antimycobacterial activity of recent quinoxaline derivatives and discusses their structure—activity relationship for designing new analogs with improved activity. Methods. The review compiles recent studies published between January 2011 and April 2021. Results. The final total of 23 studies were examined. Conclusions. Data from studies of quinoxaline and quinoxaline 1,4-di-N-oxide derivatives highlight that specific derivatives show encouraging perspectives in the treatment of Mycobacterium tuberculosis and the recent growing interest for these scaffolds. These interesting results warrant further investigation, which may allow identification of novel antitubercular candidates based on this scaffold.
Top-30
Journals
|
1
2
3
4
|
|
|
ChemistrySelect
4 publications, 11.43%
|
|
|
RSC Advances
3 publications, 8.57%
|
|
|
Journal of Molecular Structure
3 publications, 8.57%
|
|
|
Pharmaceuticals
2 publications, 5.71%
|
|
|
European Journal of Medicinal Chemistry
2 publications, 5.71%
|
|
|
Environmental Monitoring and Assessment
1 publication, 2.86%
|
|
|
Bioorganic Chemistry
1 publication, 2.86%
|
|
|
Green Chemistry
1 publication, 2.86%
|
|
|
Tetrahedron Letters
1 publication, 2.86%
|
|
|
Advances in Heterocyclic Chemistry
1 publication, 2.86%
|
|
|
Archiv der Pharmazie
1 publication, 2.86%
|
|
|
Chemistry
1 publication, 2.86%
|
|
|
Journal of Heterocyclic Chemistry
1 publication, 2.86%
|
|
|
Drugs and Drug Candidates
1 publication, 2.86%
|
|
|
Organic and Biomolecular Chemistry
1 publication, 2.86%
|
|
|
Synlett
1 publication, 2.86%
|
|
|
Journal of Organic Chemistry
1 publication, 2.86%
|
|
|
RSC Medicinal Chemistry
1 publication, 2.86%
|
|
|
European Journal of Organic Chemistry
1 publication, 2.86%
|
|
|
Synthetic Communications
1 publication, 2.86%
|
|
|
ChemMedChem
1 publication, 2.86%
|
|
|
MicrobiologyOpen
1 publication, 2.86%
|
|
|
International Journal of Molecular Sciences
1 publication, 2.86%
|
|
|
Journal of Inorganic Biochemistry
1 publication, 2.86%
|
|
|
Mendeleev Communications
1 publication, 2.86%
|
|
|
Molecular Diversity
1 publication, 2.86%
|
|
|
1
2
3
4
|
Publishers
|
1
2
3
4
5
6
7
8
9
|
|
|
Wiley
9 publications, 25.71%
|
|
|
Elsevier
9 publications, 25.71%
|
|
|
Royal Society of Chemistry (RSC)
6 publications, 17.14%
|
|
|
MDPI
5 publications, 14.29%
|
|
|
Springer Nature
2 publications, 5.71%
|
|
|
Georg Thieme Verlag KG
1 publication, 2.86%
|
|
|
American Chemical Society (ACS)
1 publication, 2.86%
|
|
|
Taylor & Francis
1 publication, 2.86%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 2.86%
|
|
|
1
2
3
4
5
6
7
8
9
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.